La Jolla Pharmaceutical — Investor Presentation (July 2015)
31 slides from La Jolla Pharmaceutical's investor presentation, Jul 27, 2015
Slide 1: Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases
July 2015 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp
Slide 3: Overview of LJPC
Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position
Slide 4: Mission Statement
Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life- threatening diseases by discovering and developing innovative therapies 4
Slide 5: LJPC Corporate Highlights
LJPC Corporate Highlights • Focused on de-risked product opportunities Naturally occurring peptides with well-understood biological functions Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH) Phase 3 registration study acti
Slide 6: Product Pipeline
Product Pipeline LJPC-501 Angiotensin II LJPC-401 Hepcidin Other R&D Indication IND Phase 1 Phase 2 Phase 3 UnderwayCompleted Planned HRS CRH End 2015 Various H2 2016 HH Phase 1/2 Mid- 2015 LJPC-30Sa & LJPC-30Sb Gentamicin Derivatives Bacterial Infections Rare Genetic Disorders Galectin-3 Inhibitor
Slide 7: Overview of LJPC: LJPC-501
Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position
Slide 8: LJPC-501: Overview
LJPC-501: Overview • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current t
Slide 9: Three Systems Work in Harmony to Regulate Blood Pressure
Three Systems Work in Harmony to Regulate Blood Pressure Current therapeutic options for the treatment of acute hypotension only leverage the adrenal system and vasopressin system The Body’s Three Systems that Regulate Blood Pressure 9
Slide 10: High Doses of Catecholamines Increase Mortality
High Doses of Catecholamines Increase Mortality 1Sviri et al, J. of Crit Care, 29;157-160, 2014 • Catecholamines (i.e., norepinephrine, epinephrine and dopamine) cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality1 0 10 20 30 40 50 60 70 80 90 Low Dose Hi
Slide 11: Norepinephrine Dose Decreases with Angiotensin II
Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure Source: Chawla et al, Critical Care, 18:534, 2014 0 5 10 15 20 25 30 35 40 45 50 Pre2 Pre1 Hr0 Hr1 Hr2 Hr3 Hr4 Hr5 Hr6 Post1 Post2 N or ep in ep hr in e D os e (m cg /m in ) Placebo AT-II Arm Angio dose placebo grou
Slide 12: LJPC-501: Phase 3 Trial in CRH
LJPC-501: Phase 3 Trial in CRH SPA Agreement with FDA Reached, Trial Enrolling • ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial initiated in March 2015 • Randomized, placebo-controlled, double-blind Phase 3 trial • Patient population: catecholamine-resistant, based on amount o
Slide 13: LJPC-501: Market Opportunity - Large Target Population
LJPC-501: Market Opportunity Large Target Population Total Annual Hospitalized U.S. Population with Severe Hypotension Applicable Severe Hypotension: 65% Catecholamine-Treated Patients: 92% Catecholamine-Resistant* Patients: 38% LJPC-501 Target Market 555,479 361,684 332,189 126,232 *Catecholamine-r
Slide 14: LJPC-501: Market Opportunity - Attractive Pricing Potential
LJPC-501: Market Opportunity Attractive Pricing Potential Prices of Hospital-Based Drugs Reimbursed under DRGs Source: Wolters Kluwer PriceRx Pro, product package inserts, IMS Health inpatient/outpatient hospital charge master Catecholamine-Resistant* Catecholamine-Responsive Average total cost per
Slide 15: LJPC-501: Market Opportunity - Strong Interest
LJPC-501: Market Opportunity Strong Interest Even among P&T Decision Makers Robust (N=100) survey of physicians, 50% of which are P&T decision makers, shows strong interest based on evidence in primary endpoint alone Source: IMS Health survey, 2015 Endpoints Achieved Scenario 1 Scenario 2 Scenario 3
Slide 16: Summary of LJPC-501
Summary of LJPC-501 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current
Slide 17: Overview of LJPC: LJPC-401
Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position
Slide 18: LJPC-401: Overview
LJPC-401: Overview • LJPC-401 is a novel formulation of hepcidin, a naturally occurring regulator of iron absorption and distribution • Hereditary hemochromatosis (HH) is a disease characterized by a deficiency of hepcidin that results in excessive iron accumulation, which is toxic to vital organs s
Slide 19: Hepcidin: The Insulin of Iron Metabolism
Hepcidin: The Insulin of Iron Metabolism • Hepcidin: the insulin of iron metabolism Regulates iron absorption and disposition in all organs Rapid and sustained lowering of iron levels • Progress SQ formulation developed Completed toxicology • Phase 1 data in 2015 Including serum iron data
Slide 20: LJPC-401: Phase 1 Development Plan
LJPC-401: Phase 1 Development Plan • Key endpoint includes effect on serum iron levels Early insight into LJPC-401’s efficacy using clinically relevant endpoint Study to start in mid-2015 – results will be available by end of 2015 OBJECTIVES: determine safety of escalating doses of LJPC-401 in N
Slide 21: LJPC-401: Market Overview
LJPC-401: Market Overview • Hereditary Hemochromatosis (HH) Most common genetic disease in Caucasians Silent Killer - Iron accumulation can lead to liver cirrhosis, liver cancer, heart disease and/or failure, dementia and diabetes No FDA-approved treatment Current treatments don’t address th
Slide 22: Overview of LJPC: LJPC-30Sa/b
Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position
Slide 23: LJPC-30Sa/b: Overview
LJPC-30Sa/b: Overview • LJPC-30Sa and LJPC-30Sb are purified derivatives of gentamicin, which retain biologic activity but lack traditional kidney toxicity • Gentamicin: FDA-approved, standard-of-care for serious Gram-negative bacterial infections Mixture of several distinct but closely related ch
Slide 24: LJPC-30Sa/b: Potential for Improved Clinical Profile
Next-generation improved gentamicin derivative 1. Retain activity LJPC-30Sa/b: Potential for Improved Clinical Profile 2. Improve safety 0.0 4.0 8.0 12.0 16.0 placebo next-generation gentamicin derivative gentamicin In hi bi tio n/ ki ll zo ne (m m ) B.subtilus K.pneumonieae (kill) K.pneumonieae (in
Slide 25: LJPC-30Sa/b: Mechanism of Action
Gentamicin induces errors in the translation of genes into proteins Bacteria LJPC-30Sa/b: Mechanism of Action Can Be Leveraged Down Two Development Paths Alters protein synthesis leading to cell death Alters protein synthesis to allow read through of stop-codon mutations Humans 25
Slide 26: LJPC-30Sa/b: Market Opportunity
LJPC-30Sa/b: Market Opportunity • Antibiotic opportunity = $500+ million per year in U.S. Market could expand with a safer alternative – Increased duration of therapy, increased penetration, and/or new indications • Other large potential market opportunity in rare genetic disorders, such as cystic
Slide 27: LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis
LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis References: Sermet-Gaudelus et al, BMC Medicine, 5:5, 2007; Wilchanski et al, NEJM, 349:1433-41, 2003; Clancy J.P. et al, Am J Respir Crit Care Med, 163:1683-1692, 2001 • Three, independent studies suggest gentamicin helps read through stop-c
Slide 28: Overview of LJPC: Financial Position
Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position
Slide 29: Financial Position
Financial Position Cash resources expected to fund Company through 2016 Condensed Balance Sheet Data As of Mar 31, 2015 (in millions) Cash $42.7 Total liabilities $2.6 Total shareholders’ equity $43.0 Fully Diluted, As-Converted Shares Outstanding* 24,019,500 *Includes common stock, preferred stock
Slide 30: LJPC Investment Summary
LJPC Investment Summary • Focused on de-risked product opportunities Naturally occurring peptides with well-understood biological functions Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH) Phase 3 registration study active
Slide 31: Thank You
: Pharmaceuti Thank You
LA Jolla Pharmaceutical — Investor Presentation (July 2015) on 6ix